- Home
- RACC vs NTHI Comparison
RACC vs NTHI Comparison
Compare RACC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RACC | NTHI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8M | 114.6M |
| IPO Year | 2026 | N/A |
Fundamental Metrics
Financial Performance| Metric | RACC | NTHI |
|---|---|---|
| Price | $21.40 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 54.7K | ★ 59.0K |
| Earning Date | N/A | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.39 | $3.01 |
| 52 Week High | $23.00 | $12.99 |
Technical Indicators
Market Signals| Indicator | RACC | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 89.21 | 38.18 |
| Support Level | $10.44 | $3.01 |
| Resistance Level | N/A | $4.59 |
| Average True Range (ATR) | 0.97 | 0.38 |
| MACD | 0.46 | 0.00 |
| Stochastic Oscillator | 94.54 | 31.23 |
Price Performance
Historical ComparisonAbout RACC Research Alliance Corporation III Class A Ordinary Shares
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.